MCID: RLP008
MIFTS: 35

Relapsed/refractory Diffuse Large B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Relapsed/refractory Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Relapsed/refractory Diffuse Large B-Cell Lymphoma:

Name: Relapsed/refractory Diffuse Large B-Cell Lymphoma 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0080192

Summaries for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Disease Ontology : 12 A diffuse large B-cell lymphoma characterized by less than 50 percent decrease in lesion size with induction therapy or the appearance of new lesions or the appearance of new lesions after attainment of complete remission.

MalaCards based summary : Relapsed/refractory Diffuse Large B-Cell Lymphoma is related to diffuse large b-cell lymphoma and b-cell lymphoma. An important gene associated with Relapsed/refractory Diffuse Large B-Cell Lymphoma is FOXP1 (Forkhead Box P1), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Measles. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and endothelial, and related phenotypes are hematopoietic system and immune system

Related Diseases for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Diseases related to Relapsed/refractory Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Related Disease Score Top Affiliating Genes
1 diffuse large b-cell lymphoma 31.5 MYC FOXP1 CD79B CD19
2 b-cell lymphoma 31.2 MYC FOXP1 CD79B CD22 CD19
3 lymphoma, non-hodgkin, familial 30.1 MYC CD79B CD28 CD22 CD19
4 lymphoma 11.1
5 neutropenia 10.7
6 lymphoma, hodgkin, classic 10.6
7 thrombocytopenia 10.6
8 primary mediastinal b-cell lymphoma 10.4
9 thrombocytopenia 3 10.2
10 graft-versus-host disease 10.2
11 mantle cell lymphoma 10.2
12 follicular lymphoma 10.2
13 aphasia 10.2
14 lymphadenitis 10.2
15 hepatitis b 10.2
16 hepatitis 10.2
17 lymphopenia 10.2
18 speech disorder 10.2
19 47,xyy 10.2
20 48,xyyy 10.2
21 acute graft versus host disease 10.2
22 granulocytopenia 10.2
23 encephalopathy 10.2
24 tremor 10.2
25 testicular lymphoma 10.2 FOXP1 CD79B
26 refractory hematologic cancer 10.2 CD22 CD19
27 refractory hairy cell leukemia 10.2 CD22 CD19
28 eye lymphoma 10.2 CD22 CD19
29 plasma protein metabolism disease 10.2 CD79B CD19
30 capillary leak syndrome 10.1 CD22 CD19
31 mulchandani-bhoj-conlin syndrome 10.1 FCRL5 CD19
32 anemia, autoimmune hemolytic 10.1 CTLA4 CD19
33 alpha chain disease 10.1 FOXP1 CD22 CD19
34 autoimmune disease of blood 10.1 CTLA4 CD19
35 chickenpox 10.1 CTLA4 CD19
36 b cell prolymphocytic leukemia 10.1 MYC CD19
37 spleen cancer 10.1 CD79B CD22 CD19
38 cll/sll 10.1 CD79B CD22 CD19
39 lymphoplasmacytic lymphoma 10.1 CD79B CD22 CD19
40 intravascular large b-cell lymphoma 10.1 MYC CD79B
41 splenic disease 10.0 CD22 CD19
42 autoimmune cardiomyopathy 10.0 CTLA4 CD28
43 type 1 diabetes mellitus 21 10.0 CTLA4 CD28
44 richter's syndrome 10.0 MYC CD19
45 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.9 CTLA4 CD28
46 marginal zone b-cell lymphoma 9.9 FOXP1 CD79B CD22 CD19
47 central nervous system hematologic cancer 9.9 MYC CD79B CD19
48 lymphoproliferative syndrome 2 9.9 CTLA4 CD28
49 primary bacterial infectious disease 9.9 CTLA4 CD28 CD19
50 adult lymphoma 9.9 MYC CD22 CD19

Graphical network of the top 20 diseases related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:



Diseases related to Relapsed/refractory Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Relapsed/refractory Diffuse Large B-Cell Lymphoma

MGI Mouse Phenotypes related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 CD19 CD22 CD247 CD28 CD37 CD79B
2 immune system MP:0005387 9.61 CD19 CD22 CD247 CD28 CD37 CD79B
3 normal MP:0002873 9.1 CD19 CD247 CD28 CD79B CTLA4 MYC

Drugs & Therapeutics for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Drugs for Relapsed/refractory Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
4
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6 Gastrointestinal Agents Phase 2, Phase 3
7 Hormone Antagonists Phase 2, Phase 3
8 Antiemetics Phase 2, Phase 3
9 Immunosuppressive Agents Phase 3
10 Hormones Phase 2, Phase 3
11 glucocorticoids Phase 2, Phase 3
12 Antineoplastic Agents, Hormonal Phase 2, Phase 3
13 Anti-Inflammatory Agents Phase 2, Phase 3
14
Zanubrutinib Approved, Investigational Phase 2 1691249-45-2
15
Blinatumomab Approved, Investigational Phase 2 853426-35-4
16
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
17
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
18
nivolumab Approved Phase 1, Phase 2 946414-94-4
19
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
20
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
21
Idelalisib Approved Phase 2 870281-82-6
22
ofatumumab Approved Phase 2 679818-59-8 6918251
23
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
24
Mogamulizumab Approved, Investigational Phase 1, Phase 2 1159266-37-1
25
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
27
Venetoclax Approved, Investigational Phase 1, Phase 2 1257044-40-8 49846579
28
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
29
Lenalidomide Approved Phase 2 191732-72-6 216326
30
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
31
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
32
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
33
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
34 Interleukin-12 Phase 2
35 Protein Kinase Inhibitors Phase 2
36 Antibodies, Bispecific Phase 2
37 BI 836826 Phase 2
38 Antiviral Agents Phase 2
39 Antimetabolites Phase 2
40 Anti-Infective Agents Phase 2
41 Immunoconjugates Phase 2
42 Antibodies, Blocking Phase 1, Phase 2
43 Tubulin Modulators Phase 1, Phase 2
44 Antimitotic Agents Phase 1, Phase 2
45 Immunoglobulins, Intravenous Phase 1, Phase 2
46 Dermatologic Agents Phase 1, Phase 2
47 Keratolytic Agents Phase 1, Phase 2
48 Antibodies, Monoclonal Phase 1, Phase 2
49 Podophyllotoxin Phase 1, Phase 2 518-28-5
50 Immunoglobulin G Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Completed NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
2 A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) Recruiting NCT04442022 Phase 2, Phase 3 Selinexor (combination therapy);Selinexor (combination therapy);Selinexor (combination therapy);Placebo matching for Selinexor (combination therapy);Rituximab (combination therapy);Rituximab (combination therapy);Gemcitabine (combination therapy);Dexamethasone (combination therapy);Cisplatin (combination therapy);Selinexor (continuous therapy);Placebo matching for Selinexor (continuous therapy)
3 A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT04408638 Phase 3 Obinutuzumab;Glofitamab;Rituxumab;Tocilizumab;Gemcitabine;Oxaliplatin
4 A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT04182204 Phase 3 Polatuzumab Vedotin;Rituximab;Gemcitabine;Oxaliplatin
5 A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting NCT04628494 Phase 3 Investigator's Choice Chemotherapy
6 A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma Active, not recruiting NCT03391466 Phase 3 Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.;Cyclophosphamide;Fludarabine
7 Single-Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL-12) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy Unknown status NCT02544724 Phase 2
8 Phase 2 Study of Cytarabine in Association With Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma Unknown status NCT02758925 Phase 2 Rituximab;Bendamustine;Cytarabine
9 Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT) Completed NCT02374424 Phase 2 GA101_DHAP
10 A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and R/R Indolent Lymphoma Completed NCT03520920 Phase 2 Zanubrutinib;Rituximab
11 A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Completed NCT01118845 Phase 2 SyB L-0501;Rituximab
12 Torch: A Phase II Study to Determine the Safety and Efficacy of the Dual mTORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT02752204 Phase 2 AZD 2014;Rituximab
13 A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-cell Lymphoma Completed NCT01354392 Phase 1, Phase 2 AZD1152
14 An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT01741792 Phase 2 Blinatumomab
15 Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations Completed NCT02674750 Phase 2 CUDC-907
16 An Open Label Multicenter Phase Ib/II Trial to Determine the Dose of BI 836826 in Combination With Gemcitabine and Oxaliplatin (GemOx) and the Efficacy of BI 836826-GemOx Versus Rituximab (R)- GemOx (R-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL) Who Are Not Eligible for, or Have Relapsed/Progressed After Autologous/Allogeneic Stem Cell Transplant Completed NCT02624492 Phase 2 BI 836826;GemOx;Rituximab;GemOx
17 An Open-label, Non-randomized Phase 2 Study of Ofatumomab (O) in Combination With ICE (Ifosfamide, Carboplatin, Etoposide)-Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT02412267 Phase 2 O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
18 Everolimus in Combination With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Completed NCT00869999 Phase 2 Everolimus;rituximab
19 An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting NCT03992339 Phase 2 ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
20 A Multicenter, Open-Label Study to Investigate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Recruiting NCT04438005 Phase 2 ICP-022
21 Phase I/II Trial of Venetoclax in Combination With R-ICE (V+RICE) Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT03064867 Phase 1, Phase 2 Venetoclax;Rituximab;Ifosfamide;Carboplatin;Etoposide
22 A Phase 2 Study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting NCT04665765 Phase 2 Carboplatin;Etoposide;Ifosfamide;Polatuzumab Vedotin
23 A Phase II Study of Ibrutinib With R-ICE Chemotherapy for Transplant-eligible Relapsed/Refractory Diffuse Large B-cell Lymphoma Followed by Ibrutinib Maintenance in Patients Not Achieving a Complete Response at Pre-transplant Interim Assessment Recruiting NCT02955628 Phase 2 Ibrutinib-RICE
24 A Multi-center Phase Ib/II Trial of Nivolumab/Ipilimumab-Primed Immunotransplant for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients. Recruiting NCT03305445 Phase 1, Phase 2 Ipilimumab;Nivolumab
25 Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Recruiting NCT03484819 Phase 2 Copanlisib Hydrochloride
26 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia Recruiting NCT04502394 Phase 1, Phase 2 KRT-232;acalabrutinib
27 Chidamide Combined With R-GemOx(Rituximab、Gemcitabine Plus Oxaliplatin) Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma: a Multi-center, Single Arm, Phase II Study Recruiting NCT04022005 Phase 2 Chidamide, Rituximab, Gemcitabine,Oxaliplatin
28 A Phase II Trial of Idelalisib in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Active, not recruiting NCT03576443 Phase 2 Idelalisib
29 Phase I/Ib Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting NCT01959698 Phase 1, Phase 2 Carboplatin;Carfilzomib;Etoposide;Ifosfamide
30 A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab, Etoposide, and High-dose Ara-C (OVA), Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting NCT01555541 Phase 2 Ofatumumab;Etoposide;Cytarabine
31 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting NCT02227251 Phase 2 Selinexor
32 A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma Active, not recruiting NCT03309878 Phase 1, Phase 2
33 A Phase II Study of Anti-PD-1 Antibody (Sintilimab) Plus Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Second-line Salvage Therapy in Patients With Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) Not yet recruiting NCT04659434 Phase 2 Sintilimab
34 Copanlisib in Combination With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma: a Multicentric Phase II Trial Not yet recruiting NCT04433182 Phase 2 Copanlisib
35 A Phase II Study of Epigenetic Priming Using Azacitidine Followed by Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not yet recruiting NCT03719989 Phase 2 azacitidine plus R-GDP
36 A Phase I/II Study of Copanlisib Plus Venetoclax for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Not yet recruiting NCT04572763 Phase 1, Phase 2 Copanlisib;Venetoclax
37 A Single-arm, Open-label, Multicenter, Phase II Clinical Trials of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not yet recruiting NCT04610970 Phase 2 TQ-B3525 tablets
38 A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated NCT00978432 Phase 2 RAD001;LBH589;Doublet (RAD001 and LBH589)
39 Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Terminated NCT00968331 Phase 2 Lenalidomide plus Rituximab
40 Panobinostat in Combination With Rituximab For Relapsed/Refractory Diffuse Large B Cell Lymphoma Terminated NCT01282476 Phase 2 Panobinostat with Rituximab
41 A Phase II Study of VDR (VELCADE™, DOXIL® and RITUXAN™) in Relapsed/Refractory Diffuse Large B-cell Lymphoma Terminated NCT00851552 Phase 2 bortezomib;pegylated liposomal doxorubicin hydrochloride
42 A Phase I/II Study of Methylselenocysteine (MSC) in Combination With Immunochemotherapy (R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Withdrawn NCT00829205 Phase 1, Phase 2 carboplatin;etoposide;ifosfamide
43 Open-Label, Dose Escalation/Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and/or High-Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 Gene Rearrangements Completed NCT03255096 Phase 1 RO6870810;Venetoclax;Rituximab
44 A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Completed NCT02220842 Phase 1 Atezolizumab;Obinutuzumab;Tazemetostat
45 A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study of Bruton Tyrosine Kinase (BTK) Inhibitor, Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT04436107 Phase 1 Zanubrutinib;Lenalidomide;Rituximab
46 Phase I Dose Escalation Study of Radiotherapy and Durvalumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): The RaDD Study Recruiting NCT03610061 Phase 1 Durvalumab
47 A Phase I, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Glofitamab as Single Agent Administered After a Fixed, Single Dose Pretreatment of Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT04657302 Phase 1 Obinutuzumab;Glofitamab;Tocilizumab
48 A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant Recruiting NCT02658968 Phase 1 Betalutin
49 Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03450343 Phase 1 Oral azacitidine;R-ICE
50 A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma Recruiting NCT03440567 Phase 1 Avelumab;Carboplatin;Etoposide Phosphate;Ibrutinib;Ifosfamide

Search NIH Clinical Center for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Genetic Tests for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Anatomical Context for Relapsed/refractory Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:

40
T Cells, Bone Marrow, Endothelial

Publications for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Articles related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 144)
# Title Authors PMID Year
1
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. 61
33529419 2021
2
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. 61
33274677 2021
3
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. 61
33528286 2021
4
Relapsed / Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. 61
33661547 2021
5
Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. 61
32782349 2021
6
[How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC]. 61
33610284 2021
7
[Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. 61
33678408 2021
8
Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. 61
33770460 2021
9
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. 61
33431309 2021
10
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. 61
33593414 2021
11
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. 61
33619641 2021
12
Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma. 61
33115291 2021
13
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. 61
33523334 2021
14
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. 61
33777778 2021
15
Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review. 61
33796398 2021
16
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. 61
32981410 2021
17
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. 61
33414443 2021
18
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma. 61
32954807 2021
19
Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. 61
33485834 2020
20
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. 61
33632668 2020
21
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. 61
32705923 2020
22
[Clinical Value of Serum Amyloid A and Misfolded Transthyretin for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients]. 61
33283721 2020
23
Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era. 61
33169198 2020
24
Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. 61
32945942 2020
25
Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. 61
33288485 2020
26
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. 61
32633177 2020
27
Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience. 61
33277224 2020
28
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective. 61
32780608 2020
29
Correction to: Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. 61
32980889 2020
30
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. 61
33180899 2020
31
Classifying 2-year recurrence in patients with dlbcl using clinical variables with imbalanced data and machine learning methods. 61
32544778 2020
32
Advances in chimeric antigen receptor T cells. 61
32925186 2020
33
Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin. 61
32985934 2020
34
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. 61
32339368 2020
35
New tricks for old drugs: combination of rituximab and two nanoparticle-delivered chemotherapy drugs, albumin-bound paclitaxel and pegylated liposomal doxorubicin, in the treatment of relapsed/refractory diffuse large B cell lymphoma. 61
32508171 2020
36
Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab. 61
32886277 2020
37
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma. 61
33028076 2020
38
Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies. 61
32576502 2020
39
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. 61
32448949 2020
40
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. 61
32060403 2020
41
Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients. 61
32974076 2020
42
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. 61
32500753 2020
43
Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplants for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Is More Actually Less? 61
32045653 2020
44
R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. 61
31682979 2020
45
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. 61
32325898 2020
46
Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. 61
32271898 2020
47
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. 61
32271899 2020
48
Salvage Chemotherapy Followed by Autologous Stem-Cell Transplantation Using Targeted Busulfan for Refractory Diffuse Large B-Cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease. 61
31787588 2020
49
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. 61
32045475 2020
50
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. 61
32074277 2020

Variations for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Expression for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Relapsed/refractory Diffuse Large B-Cell Lymphoma.

Pathways for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Pathways related to Relapsed/refractory Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.06 CTLA4 CD79B CD28 CD247 CD22 CD19
2
Show member pathways
12.52 MYC CD28 CD247 CD19
3
Show member pathways
12.4 CD79B CD28 CD22 CD19
4
Show member pathways
12.11 CTLA4 CD28 CD247
5
Show member pathways
11.91 CTLA4 CD28 CD247
6 11.83 CTLA4 CD28 CD22
7 11.74 CD247 CD22 CD19
8
Show member pathways
11.65 MYC CD79B CD22 CD19
9
Show member pathways
11.52 CD79B CD22 CD19
10 11.43 CD37 CD22 CD19
11
Show member pathways
11.23 MYC CD28 CD247
12 11.18 CTLA4 CD28 CD247
13 11.09 CD28 CD247
14 11.03 CTLA4 CD28
15 10.99 CD79B CD28 CD22 CD19
16 10.97 CD28 CD247

GO Terms for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Cellular components related to Relapsed/refractory Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.91 MYC FCRL5 CTLA4 CD79B CD37 CD28
2 integral component of plasma membrane GO:0005887 9.5 FCRL5 CTLA4 CD79B CD37 CD28 CD22
3 immunological synapse GO:0001772 9.32 CD37 CD28
4 protein complex involved in cell adhesion GO:0098636 9.16 CTLA4 CD28
5 external side of plasma membrane GO:0009897 9.02 CTLA4 CD79B CD28 CD22 CD19

Biological processes related to Relapsed/refractory Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.62 CTLA4 CD79B CD247 CD19
2 regulation of immune response GO:0050776 9.61 CD247 CD22 CD19
3 T cell receptor signaling pathway GO:0050852 9.54 CTLA4 CD28 CD247
4 B cell receptor signaling pathway GO:0050853 9.43 CTLA4 CD79B CD19
5 regulation of defense response to virus by virus GO:0050690 9.4 CD28 CD247
6 regulation of regulatory T cell differentiation GO:0045589 9.16 CTLA4 CD28
7 regulation of T cell proliferation GO:0042129 8.96 CTLA4 CD28
8 cell surface receptor signaling pathway GO:0007166 8.92 FCRL5 CD79B CD28 CD247

Molecular functions related to Relapsed/refractory Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.13 FCRL5 CD79B CD247
2 core promoter sequence-specific DNA binding GO:0001046 8.62 MYC FOXP1

Sources for Relapsed/refractory Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....